Citigroup Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price target cut by equities research analysts at Citigroup from $125.00 to $122.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the healthcare product maker’s stock. Citigroup‘s price target indicates a potential upside of 18.86% from the stock’s current price.

ABT has been the subject of a number of other research reports. BTIG Research lowered their target price on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a research note on Thursday. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and upped their price target for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Robert W. Baird raised their price objective on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Royal Bank Of Canada dropped their target price on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.32.

Abbott Laboratories Trading Up 2.1%

NYSE ABT traded up $2.13 during trading on Thursday, hitting $102.64. The company had a trading volume of 10,564,601 shares, compared to its average volume of 11,314,207. The company’s fifty day moving average is $105.47 and its 200-day moving average is $98.28. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market cap of $177.61 billion, a price-to-earnings ratio of 33.22, a price-to-earnings-growth ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. During the same quarter in the previous year, the firm posted $1.30 EPS. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, sell-side analysts predict that Abbott Laboratories will post 5.53 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABT. Farther Finance Advisors LLC grew its holdings in Abbott Laboratories by 14.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock valued at $8,339,000 after buying an additional 10,431 shares in the last quarter. Juncture Wealth Strategies LLC bought a new stake in Abbott Laboratories in the 3rd quarter worth approximately $658,000. Aureus Asset Management LLC raised its holdings in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after acquiring an additional 66,422 shares in the last quarter. Thompson Investment Management Inc. raised its holdings in shares of Abbott Laboratories by 786.0% during the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock worth $1,276,000 after acquiring an additional 12,474 shares in the last quarter. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Abbott Laboratories during the 2nd quarter valued at approximately $4,889,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter sales rose 14.5% year over year to $13.01 billion, slightly exceeding estimates, while adjusted EPS of $1.42 matched consensus and improved from $1.30 a year earlier. Abbott also reaffirmed its full-year EPS guidance. Abbott third-quarter results
• Positive Sentiment: Analysts remain constructive despite trimming price targets. Wells Fargo raised its target to $119 and maintained an overweight rating, while RBC, JPMorgan, TD Cowen and BTIG retained positive ratings with targets implying roughly 15%–22% upside. Robert W. Baird also raised its target to $123.
• Positive Sentiment: Abbott received European CE Mark authorization for its Cologuard Plus colorectal cancer screening test, expanding the potential market for its diagnostics business. Cologuard Plus European authorization
• Neutral Sentiment: Abbott plans a tax-free spin-off of its approximately $8.5 billion global Nutrition business into a separate public company by the end of 2027. Management expects the separation to create more focused investment strategies and accelerate Abbott’s sales growth and margins, but execution and valuation remain future uncertainties. Abbott Nutrition spin-off announcement
• Negative Sentiment: Abbott lowered its 2026 sales-growth outlook, citing diabetes-related pricing pressure and weakness in parts of its electrophysiology and medical-device portfolio. Investors viewed the guidance reduction as more important than the quarterly revenue beat. Abbott lowers 2026 sales forecast
• Negative Sentiment: India’s food regulator questioned Abbott and Nestlé over infant-formula claims, creating a localized regulatory and reputational risk for Abbott’s Nutrition business. India infant-formula regulatory notice

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.